Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + Atezolizumab vs Atezolizumab as Maintenance in ES-SCLC
NCT05091567Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Nov 2021
- Primary completion
- Jul 2024
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of lurbinectedin in small cell lung cancer (SCLC) (2 arms), sponsored by Roche. Primary endpoints: Progression-Free Survival up to 26 months and Overall Survival up to 26 months. Started Nov 2021; status: active, not recruiting.
02
Drugs
lurbinectedin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05091567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05091567.